Abstract:Rabies, caused by the rabies virus (RABV), is the most fatal zoonotic disease. It is a neglected tropical disease which remains a major public health problem, causing approximately 59,000 deaths worldwide annually. Despite the existence of effective vaccines, the high incidence of human rabies is mainly linked to tedious vaccine immunisation procedures and the overall high cost of post-exposure prophylaxis. Therefore, it is necessary to develop an effective vaccine that has a simple procedure and is affordable to prevent rabies infection in humans. RABV belongs to the genus Lyssavirus and family Rhabdoviridae. Previous phylogenetic analyses have identified seven major clades of RABV in China (China I-VII), confirmed by analysing nucleotide sequences from both the G and N proteins. This study evaluated the immunogenicity and protective capacity of SYS6008, an mRNA rabies vaccine expressing rabies virus glycoprotein, in mice and cynomolgus macaques. We demonstrated that SYS6008 induced sufficient levels of rabies neutralising antibody (RVNA) in mice. In addition, SYS6008 elicited strong and durable RVNA responses in vaccinated cynomolgus macaques. In the pre-exposure prophylaxis murine model, one or two injections of SYS6008 at 1/10 or 1/30 of dosage provided protection against a challenge with a 30-fold LD<sub>50</sub> of rabies virus (China I and II clades). We also demonstrated that in the post-exposure prophylaxis murine model, which was exposed to lethal rabies virus (China I-VII clades) before vaccination, one or two injections of SYS6008 at both 1/10 and 1/30 dosages provided better protection against rabies virus challenge than the immunization by five injections of commercial vaccines at the same dosage. In addition, we proved that SYS6008-induced RVNAs could neutralise RABV from the China I-VII clades. Finally, 1/10 of the dosage of SYS6008 was able to stimulate significant RABV-G specificity in the T cell response. Furthermore, we found that SYS6008 induced high cellular immunity, including RABV-G-specific T cell responses and memory B cells. Our results imply that the SYS6008 rabies vaccine, with a much simpler vaccination procedure, better immunogenicity, and enhanced protective capacity, could be a candidate vaccine for post-exposure prophylaxis of rabies infections.

Molecular Engineering of AIE Photosensitizers for Inactivation of Rabies Virus

Treat the “untreatable” by a Photothermal Agent: Triggering Heat and Immunological Responses for Rabies Virus Inactivation

Novel Approaches to the Prevention and Treatment of Rabies.

Aptamer and RVG Functionalized Gold Nanorods for Targeted Photothermal Therapy of Neurotropic Virus Infection in the Mouse Brain

Mechanism of action of phthalazinone derivatives against rabies virus

Preexposure and Postexposure Prophylaxis of Rabies With Adeno-Associated Virus Expressing Virus-Neutralizing Antibody in Rodent Models

Rabies Prophylactic and Treatment Options: An In Vitro Study of siRNA- and Aptamer-Based Therapeutics

Research Progress on Neutralizing Epitopes and Antibodies for the Rabies Virus

Small Interfering Rnas Targeting the Rabies Virus Nucleoprotein Gene

Application of a novel nanoemulsion adjuvant for rabies vaccine which stabilizes a Krebs cycle intermediate (SDH) in an animal model

Detection of Rabies Virus Via Exciton Energy Transfer Between CdTe Quantum Dots and Au Nanoparticles

RVG Peptide-Functionalized Favipiravir Nanoparticle Delivery System Facilitates Antiviral Therapy of Neurotropic Virus Infection in a Mouse Model.

[Targeted Inhibition of Rabies Virus Gene Expression by a Chimeric Multidomain Protein Mediated Shrna Delivery].

Protection Against CNS-Targeted Rabies Virus Infection is Dependent upon Type-1 Immune Mechanisms Induced by Live-Attenuated Rabies Vaccines

Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system

Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs

Clofazimine: A Promising Inhibitor of Rabies Virus

A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses

Rabies-related brain disorders: transmission dynamics and epidemic management via educational campaigns and application of nanotechnology

Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis

Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies